EUVIMEDEUVIMED entdecken
Crossref

The Role of Liquid Biopsies in Personalised Cancer Management

Audrey Galou, Ioana Maria Gavriliuc, Chloe Basile-Grall, Jana Muller, Joan Marylou Modl, Yosr Hajji, Naeem Hamza

International Journal of Biomedical and Clinical Analysis · 30.06.2026 · 6 (1) · 10-30

DOI: 10.61797/ijbca.v6i1.662 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Biomedical and Clinical Analysis, online erschienen am 30.06.2026. Verfasst von Audrey Galou und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer is a dynamic disease that requires equally dynamic tools to monitor its evolution. While tissue biopsy remains essential for tumour characterisation, its invasiveness and limited ability to capture the heterogeneity of the tumour restricts its use. Liquid biopsy offers a minimally invasive complementary approach that can partially overcome these limitations. This review summarises the principal liquid biopsy analytes, their clinical application, recent clinical studies, current limitations and future perspectives. Key analytes such as circulating tumour DNA (ctDNA) and Circulating Tumour Cells (CTCs) provide a valuable insight into the tumour biology and disease dynamics. Their analysis enables monitoring of tumour burden, detection of treatment resistance, of minimal residual disease and, in selected settings, early cancer detection. Despite its promise, several challenges remain. Current liquid biopsy technologies remain constrained by biological and analytical limits of tumour biomarker detectability. The sensitivity in early disease is often limited, increasing the risk of false negative results and a substantial proportion of cancer continue to be undetectable. Furthermore, biological noise and tumour heterogeneity may reduce the detection of circulating biomarkers. Lastly, issues related to specificity, cost and lack of standardisation continue to hinder the generalisation of clinical implementation. Overall, liquid biopsy represents a valuable complementary tool in personalised cancer management, with ongoing technological refinement and clinical validation expected to further define its role in routine oncology practice.

Zitieren

APA

Galou, A., Gavriliuc, I. M., Basile-Grall, C., Muller, J., Modl, J. M., Hajji, Y., & Hamza, N. (2026). The Role of Liquid Biopsies in Personalised Cancer Management. International Journal of Biomedical and Clinical Analysis, 6(1), 10-30. https://doi.org/10.61797/ijbca.v6i1.662

Vancouver

Galou A, Gavriliuc IM, Basile-Grall C, Muller J, Modl JM, Hajji Y, et al. The Role of Liquid Biopsies in Personalised Cancer Management. International Journal of Biomedical and Clinical Analysis. 2026;6(1):10-30. doi:10.61797/ijbca.v6i1.662

BibTeX
@article{Galou2026,
  author = {Galou, Audrey and Gavriliuc, Ioana Maria and Basile-Grall, Chloe and Muller, Jana and Modl, Joan Marylou and Hajji, Yosr and Hamza, Naeem},
  title = {The Role of Liquid Biopsies in Personalised Cancer Management},
  journal = {International Journal of Biomedical and Clinical Analysis},
  year = {2026},
  volume = {6},
  number = {1},
  pages = {10--30},
  doi = {10.61797/ijbca.v6i1.662}
}
Kostenlos starten →